Luke DR[au] - Search Results

Year	Number of Results
1964	2
1986	5
1987	3
1988	2
1989	6
1990	18
1991	11
1992	7
1993	2
1995	2
1996	2
1997	3
1998	4
1999	1
2002	1
2003	1
2005	1
2010	1
2011	1
2012	1
2013	3
2014	1
2015	1
2016	1
2017	1
2018	2
2019	1
2022	1
2023	0

1

Review of the basic and clinical pharmacology of sulfobutylether-beta-cyclodextrin (SBECD).

Luke DR, Tomaszewski K, Damle B, Schlamm HT. Luke DR, et al. J Pharm Sci. 2010 Aug;99(8):3291-301. doi: 10.1002/jps.22109. J Pharm Sci. 2010. PMID: 20213839 Review.

2

Formation of moiré interlayer excitons in space and time.

Schmitt D, Bange JP, Bennecke W, AlMutairi A, Meneghini G, Watanabe K, Taniguchi T, Steil D, Luke DR, Weitz RT, Steil S, Jansen GSM, Brem S, Malic E, Hofmann S, Reutzel M, Mathias S. Schmitt D, et al. Among authors: luke dr. Nature. 2022 Aug;608(7923):499-503. doi: 10.1038/s41586-022-04977-7. Epub 2022 Aug 17. Nature. 2022. PMID: 35978130

3

Phase 1 Study of the Pharmacology of BTI320 Before High-Glycemic Meals.

Luke DR, Lee KKY, Rausch CW, Cheng C. Luke DR, et al. Clin Pharmacol Drug Dev. 2019 Apr;8(3):395-403. doi: 10.1002/cpdd.583. Epub 2018 Jun 5. Clin Pharmacol Drug Dev. 2019. PMID: 29870598 Free PMC article. Clinical Trial.

4

Clinical Pharmacokinetics of Sulfobutylether-β-Cyclodextrin in Patients With Varying Degrees of Renal Impairment.

Hoover RK, Alcorn H Jr, Lawrence L, Paulson SK, Quintas M, Luke DR, Cammarata SK. Hoover RK, et al. Among authors: luke dr. J Clin Pharmacol. 2018 Jun;58(6):814-822. doi: 10.1002/jcph.1077. Epub 2018 Mar 26. J Clin Pharmacol. 2018. PMID: 29578585 Free PMC article. Clinical Trial.

5

Clinical Pharmacology of Delafloxacin in Patients With Hepatic Impairment.

Hoover R, Marbury TC, Preston RA, Quintas M, Lawrence LE, Paulson SK, Luke DR, Cammarata SK. Hoover R, et al. Among authors: luke dr. J Clin Pharmacol. 2017 Mar;57(3):328-335. doi: 10.1002/jcph.817. Epub 2016 Oct 14. J Clin Pharmacol. 2017. PMID: 27570245 Free PMC article. Clinical Trial.

6

Toleration of intravenous azithromycin.

Luke DR, Foulds G. Luke DR, et al. Ann Pharmacother. 1997 Sep;31(9):965-9. doi: 10.1177/106002809703100901. Ann Pharmacother. 1997. PMID: 9296232 Clinical Trial.

7

Cilastatin-insulin interaction in the rat.

Tompkins GC, Brunner LJ, Luke DR. Tompkins GC, et al. Among authors: luke dr. Drug Metab Dispos. 1989 Jan-Feb;17(1):54-7. Drug Metab Dispos. 1989. PMID: 2566470

8

Therapeutic drug monitoring of cyclosporine-lipoprotein levels.

Yau JC, Brunner LJ, Lopez-Berestein G, LeMaistre CF, Luke DR. Yau JC, et al. Among authors: luke dr. Pharmacotherapy. 1991;11(4):291-5. Pharmacotherapy. 1991. PMID: 1923909

9

Pharmacokinetics of sulfobutylether-β-cyclodextrin (SBECD) in subjects on hemodialysis.

Luke DR, Wood ND, Tomaszewski KE, Damle B. Luke DR, et al. Nephrol Dial Transplant. 2012 Mar;27(3):1207-12. doi: 10.1093/ndt/gfr472. Epub 2011 Aug 24. Nephrol Dial Transplant. 2012. PMID: 21868395

10

Time-dependent pharmacokinetics and toxicity of cyclosporine.

Luke DR, Vadiei K, Brunner LJ. Luke DR, et al. Chronobiol Int. 1988;5(4):353-62. doi: 10.3109/07420528809067781. Chronobiol Int. 1988. PMID: 3069229

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

82 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

82 results

Results by year